谢林影,马生花

免疫检查点抑制剂（immune checkpoint inhibitors，ICPis）作为一种新型抗肿瘤药物用于治疗多种不同类型肿瘤，在临床上对多种肿瘤都具有良好的治疗效果，现已成为治疗肿瘤的重要药物之一。值得关注的是，ICPis在治疗肿瘤的过程中会出现相关的免疫系统不良反应，即为免疫相关不良反应（immune-related adverse events,irAES）。irAES中的内分泌系统不良反应是其中最常见的不良反应之一，因此，对于该问题的研究具有一定的现实意义。本文主要综述了ICPis治疗肿瘤过程中内分泌系统不良反应的研究现状及进展，为临床出现此类不良反应的研究提供相关临床数据及可参考资料。对于预防此类不良反应、提高临床治疗效果的研究具有重要参考意义。

免疫检查点抑制剂；免疫相关不良反应；内分泌系统不良反应

[1] 叶强,陈小燕.免疫检查点抑制剂的内分泌毒性及临床应对策略[J].实用医学杂志,2021,37(11):1382-1386. [2] CHEN R Y,ZHU Y,SHEN Y Y,et al.The role of PD-1 signaling in health and immune-related diseases[J/OL].Frontiers in Immunology,2023,14:1163633. [3] 赵喆,唐彦,朱惠娟,等免疫检查点抑制剂引发的免疫相关不良反应研究进展[J].临床药物治疗杂志,2022,20(6):1-6. [4] 罗景梅,杨中策,潘俐,等.免疫检查点抑制剂所致内分泌不良反应处理流程研究进展[J].解放军医学杂志,2021,46(2):200-206. [5] WRIGHT J J,POWERS A C,JOHNSON D B.Endocrine toxicities of immune checkpoint inhibitors[J/OL].Nature Reviews.Endocrinology,2021,17(7):389-399. [6] PROFILI N I,CASTELLI R,GIDARO A,et al.Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors:A Narrative Review[J/OL].Journal of Clinical Medicine,2023,12(15):5161. [7] QINS,XU L,YI M,et al.Novel immune checkpoint targets:moving beyond PD-1 and CTLA-4[J/OL].Molecular Cancer,2019,18(1):155. [8] KURIMOTO C,INABA H,ARIYASU H,et al.Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors[J/OL].Cancer Science,2020,111(5):1468-1477. [9] MUIR C A,CLIFTON-BLIGH R J,LONG G V,et al.Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment[J/OL].The Journal of Clinical Endocrinology and Metabolism,2021,106(9):e3704-e3713. [10] TOI Y,SUGAWARA S,SUGISAKA J,et al.Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer[J/OL].JAMA oncology,2019,5(3):376-383. [11] OKADA N,IWAMA S,OKUJI T,et al.Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies:a prospective study[J/OL].British Journal of Cancer,2020,122(6):771-777. [12] HUSEBYE E S,CASTINETTI F,CRISENO S,et al.Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition:an ESE clinical practice guideline[J/OL].European Journal of Endocrinology,2022,187(6):G1-G21. [13] AGRAWAL L,BACAL A,JAIN S,et al.Immune checkpoint inhibitors and endocrine side effects,a narrative review[J/OL].Postgraduate Medicine,2020,132(2):206-214. [14] LANGLOIS F,VARLAMOV E V,FLESERIU M.Hypophysitis,the Growing Spectrum of a Rare Pituitary Disease[J/OL].The Journal of Clinical Endocrinology and Metabolism,2022,107(1):10-28. [15] Managing Ipilimumab-Induced Hypophysitis:Challenges and Current Therapeutic Strategies-PubMed[EB/OL].[2023-12-04].https://pubmed.ncbi.nlm.nih.gov/33061641/. [16] ROBERT C,LONG G V,BRADY B,et al.Nivolumab in previously untreated melanoma without BRAF mutation[J/OL].The New England Journal of Medicine,2015,372(4):320-330. [17] GREENFIELD D M,WALTERS S J,COLEMAN R E,et al.Quality of life,self-esteem,fatigue,and sexual function in young men after cancer:a controlled cross-sectional study[J/OL].Cancer,2010,116(6):1592-1601. [18] AMERELLER F,DEUTSCHBEIN T,JOSHI M,et al.Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study[J/OL].Pituitary,2022,25(1):152-158. [19] BARROSO-SOUSA R,BARRY W T,GARRIDO-CASTRO A C,et al.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens:A Systematic Review and Meta-analysis[J/OL].JAMA oncology,2018,4(2):173-182. [20] LU D,YAO J,YUAN G,et al.Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency:a retrospective analysis using the FAERS[J/OL].Journal of Endocrinological Investigation,2022,45(11):2131-2137. [21] HAISSAGUERRE M,HESCOT S,BERTHERAT J,et al.Expert opinions on adrenal complications in immunotherapy[J/OL].Annales D’endocrinologie,2018,79(5):539-544. [22] 丁小涵,汪新宇,杨帆,等.免疫检查点抑制剂的内分泌毒性[J].广东医科大学学报,2022,40(1):104-108. [23] WRIGHT J J,POWERS A C,JOHNSON D B.Endocrine toxicities of immune checkpoint inhibitors[J/OL].Nature Reviews.Endocrinology,2021,17(7):389-399. [24] GIROTRA M,HANSEN A,FAROOKI A,et al.The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management[J/OL].JNCI cancer spectrum,2018,2(3):pky021. [25] STELMACHOWSKA-BANAŚM,CZAJKA-ORANIEC I.Management of endocrine immune-related adverse events of immune checkpoint inhibitors:an updated review[J/OL].Endocrine Connections,2020,9(10):R207-R228. [26] TAN M H,IYENGAR R,MIZOKAMI-STOUT K,et al.Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients:a scoping review of case reports[J/OL].Clinical Diabetes and Endocrinology,2019,5:1. [27] LU J,YANG J,LIANG Y,et al.Incidence of Immune Checkpoint Inhibitor-Associated Diabetes:A Meta-Analysis of Randomized Controlled Studies[J/OL].Frontiers in Pharmacology,2019,10:1453. [28] 曾海銮,高鑫.肿瘤免疫检查点抑制剂相关内分泌疾病[J/OL].中国临床医学,2019,26(6)[2024-01-20]. [29] BAJWA R,CHEEMA A,KHAN T,et al.Adverse Effects of Immune Checkpoint Inhibitors(Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors):Results of a Retrospective Study[J/OL].Journal of Clinical Medicine Research,2019,11(4):225-236. [30] TRINH B,SANCHEZ G O,HERZIG P,et al.Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma[J/OL].Journal for Immunotherapy of Cancer,2019,7(1):52. [31] JEHL A,CUGNET-ANCEAU C,VIGOUROUX C,et al.Acquired Generalized Lipodystrophy:A New Cause of Anti-PD-1 Immune-Related Diabetes[J/OL].Diabetes Care,2019,42(10):2008-2010. [32] KUMAR V,CHAUDHARY N,GARG M,et al.Corrigendum:Current Diagnosis and Management of Immune Related Adverse Events(irAEs)Induced by Immune Checkpoint Inhibitor Therapy[J/OL].Frontiers in Pharmacology,2017,8:311. [33] HAANEN J,OBEID M,SPAIN L,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guideline for diagnosis,treatment and follow-up[J/OL].Annals of Oncology:Official Journal of the European Society for Medical Oncology,2022,33(12):1217-1238. [34] DILLARD T,YEDINAK C G,ALUMKAL J,et al.Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis:serious immune related adverse events across a spectrum of cancer subtypes[J/OL].Pituitary,2010,13(1):29-38. [35] HIGHAM C E,OLSSON-BROWN A,CARROLL P,et al.SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE:Acute management of the endocrine complications of checkpoint inhibitor therapy[J/OL].Endocrine Connections,2018,7(7):G1-G7. [36] CASTINETTI F,ALBAREL F,ARCHAMBEAUD F,et al.French Endocrine Society Guidance on endocrine side effects of immunotherapy[J/OL].Endocrine-Related Cancer,2019,26(2):G1-G18.

点击下载PDF